beat top bottom line driven eylea
dupix product languish
updat list pt
lower tg maintain op emerg
bispecif franchis appear differenti
also updat outlook slide full note
report orr rate vs chemo
keytruda vs
tecentriq vs hope win
combo race tall task
dupix continu momentum plan
new studi prurigo nodulari pemphigoid
chronic urticari alopecia areata other
profil myeloma earli proof-of-concept data
abstract
eylea higher dose mg underway run
concurr scrambl make ground
confid antibodi pozelimab goal
profil enabl subcutan dose option
self-administr partnership give
option combin srnai platform
look increas profit sanofi
shift spend kevzara praluent franchis
nice profit plenti growth ahead
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect
object report investor consid report singl factor make invest decis
eylea competitor polici risk overblown product
remain blockbust lever offens defens
beovu nv launch wac eylea
regn pre-fil eylea syring launch diabet retinopathi
provid momentum switch eylea beovu
robust franchis struggl grow day late/dollar short
start higher dose eylea trial increas durabl
linger believ ultim
outcom price reform less draconian
could drug
expand asthma patient dupi trx trajectori
found new growth rate nbrx
continu increas adult ad popul
penetr adolesc ad asthma patient
crswnp dupi sever trial addit indic
develop oncolog therapeut water front
impact stock might need wait catalyst
libtayo sale small underestim street
big oppi nsclc pivot on-going trial
although competit space unclear
succeed commerci patient death occur
bispecif antibodi trial still move
forward pivot mono bispecif trial fl dlbcl
nv beovu launch underway slew competitor
beovu launch underway specialist eager adopt
percept dri retina better eylea might
simpli reflect higher dose keep eye rgnx subretin
advm ivt gene therapi data updat well graybug
drug price reform elect year headlin risk
eylea cross-hair medicar reform
favor nation execut order still play would
issu sinc us eylea price higher ex-u elect
year come expect headlin risk persist eylea top
medicar part spend bn repres
 eylea revenu
competitor product biosimilar risk keep enthusiasm
bay pipelin doesnt enough juic
slew anti-vegf agent bispecif even devic roch
pd eye namd/dme/dr market dupix face jak
inhibitor competit ad antagonist tslp inhibitor
asthma asthma/atop derm biolog
make product conveni
innov focu oncolog justifi high spend
regn product reach market fail produc
user
quarter discuss point earn
eylea sale commentari relat defens nvss beovu launch offens
strategi diabet retinopathi pre-fil syring launch
greater clariti regard namd strategi posit vs competitor willing
rebat aggress
higher dose formul eylea reveal plan concurr trial
washington focu healthcar polici propos ipi/most favor nation etc may increas
elect season approach seek understand regn strategi mitig larg
econom damag expect headlin risk continu regard medicar reform especi enact
consid much lower price eylea partner bayer ex-u
dupix roll-out ad asthma crswnp revenu beat vs con
nbrx compar
path forward praluent price cut impact sale lot faster volum increas valu
demand increas hasnt quit risen past effect cheaper price yet
updat regard entir oncolog portfolio expect data readout
expand margin optim commerci effici
timelin catalyst
variou
yr sbla submiss
phase pediatr patient mo
phase trial peanut allergi
mono
trial grass allergi next step
phase combo isatuximab
combo isatuximab
timelin catalyst cont
phase combo
mono w/ dupix
without cemiplimab
without cemiplimab
data combo cemiplimab
proof concept data monotherapi
end
product sale line item
histor guidanc revis
previous refer tax non-gaap pre-tax incom
guidanc perform
guidanc
midpoint rang
midpoint rang
product histor sale project
repres total world-wide sale collabor sni profit loss agreement
stock trade pattern earn
here share trade histor around earn report chart left
nbi adjust red mean trade green mean trade share gener
perform well around earn part consensu hasnt fulli reflect oner spend
requir commerci partnership histor earn seem
loss share
kevzara revenu report first order analyt consensu model prior actual launch
fx trend relev
dollar gener strengthen vs regn sale
deriv europ asia pac row
eylea brand market sale yoy sale growth held strong
sale like aid avastin suppli disrupt expans
diabet retinopathi dr may help keep franchis doubl digit growth ye
although beovu might curtail growth earli stage launch
dr market expect largest growth opportun patient dr
without dme individu moder severe/sever diseas
estim eylea sale repres yoy growth
pre-fil syring fda-approv launch offer administr
conveni physician may help counteract competitor launch
ou eylea grown yoy vs result volum increas
high dose eylea enter clinic year
beovu nv hawk/harri trial mg dose
better dri properti mg data analysi
along eylea suggest left
superior dri abil tabl
refin high-dos formul
recent announc higher dose formul
eylea still lever growth expans diabet retinopathi market launch pre-
fill syring develop higher dose formul competit formid
unclear enough
continu updat earn commentari
differ previous disclos
xlr upt undisclos traget
eylea headwind competitor biosimilar watch
gene therapi long-act
anti-vegf mechan
beovu brolucizumab nv launch
price eylea wac
price war nv tri make sure non-
clinic barrier remov take
eylea product profil alon
head head trial talon wk brolo
mg vs aflibercept merlin wk
apples-to-appl comparison
doc enthusiast port deliveri system pd
archway namd complet enrol
juli pd ranibizumab refil
compar qm ivt ranibizumab chang
bcva week data expect mid
trial underway faricimab namd/dm
anti-vegf conbercept chengdu kanghong trial data
may read
otlk develop on-label avastin two studi underway
bla submiss target end
graybug ivt sunitinib malat maintain
pt singl dose mo studi
aflibercept current recruit patient
present data antibodi
namd/dme/rvo
namd pt extend beyond mo without retreat note
wk data fail gener
enthusiasm continu monitor ivt gene therapi given
competit threat rgnx produc compel result
track initi
mnta/myl biosimilar eylea trial
could reach market safeti bar
alteogen initi global clinic trial year build
foundat entri global market
chrss formycon aflibercept
biosimilar clinic develop potenti
biosimilar threat well
need keep close eye beovu nv wet launch roch ophthalmolog engin
charg forward trial port deliveri system bispecif faricimab gene therapi graybug long-
act deliveri platform program biosimilar could surpris investor
eylea headwind mfn risk
eylea fall right crosshair price debat account medicar part
 spend
price index eylea price rel basket foreign peer full
implement would erod sale
favor nation belgium ex-manufactur eylea price
show sensit analysi eylea revenue project polici implement
assumpt sale medicar total
time august plan public date propos per hhss agenda hard
deadlin implement could begin limit geographi expand sever yr
mani move piec drug price contenti issu target polit parti rebat rule
foreign drug import buy-and-bil model etc risk approach presidenti elect
stock weak attribut partli on-going rhetor surround intern
price index favor nation price polici evolv stori headlin risk
go elect year
face competitor product risk particularli beovu launch expect eylea sale fall
consider outer year
declin product sale may counteract higher dose eylea may readjust
estim view profil new formul
revenu expos medicar polici price haircut could result
signific top bottom line impact
rel consensu significantli reduc eylea outer year sale vs
light greater competit pressur well price headlin risk
dupix secur sever win includ approv sever
asthma europ adolesc ad approv fda posit
pediatr ad result approv crswnp fda posit
chmp opinion crswnp
monthli sale data reflect elev growth
trajectori believ continu
physician written script dupix
nrx
averag compar
refer chart right increas
averag compar
refer chart right increas
strong growth script present upsid consensu sale
estim predict growth
dupix offer differenti factor competitor broad
anti-atop profil reson allergist broadest label
asthma biolog help penetr still rel untouch
dupix secur approv atop dermat adolesc adult sever asthma
crswnp estim product trend toward sale eventu across indic
anticip dupix growth driven
continu expans atop dermat ad market adult pt
moderate-to-sever diseas adolesc patient number half adult estim
ad sale grow
asthma launch still earli launch
pt uncontrol moder
sever asthma elig biolog therapi
get drug
dupix broadest label biolog
project asthma sale
grow
nucala gsk gotten pre-fil
away dupi compar adv
wave trial open opportun
on-going trial pediatr ad yr
yr copd eoe allergi mono
combo read near intermedi
dupix demonstr broad efficaci across mediat diseas ad asthma crswnp
entrench posit abil address co-morbid
dupix asthma launch expect summari slide
 revenu dupix sale project
note standard quarter approv quarter first approv
nucala gsk asthma eosinophil
granulomat polyangi sale
assum averag weight kg
first dose first year
mg sc
option home administr
option home administr
mg initi sc
mg initi mg sc
option home administr
atop dermat asthma competitor
jak inhibitor look disrupt ad landscap
still remain
efficaci amaz furthermor
amgn/azn tezepelumab tslp-inhibitor two
trial navig expect read
email us excel spreadsheet compar
data competitor
antagonist fevipipr nv
radar screen base case scenario oral drug
work best moder sever high eo patient
miss primari endpoint higher
design fevipipr luster trial gina
high eo pt expect read
top-lin data jade show
iga respons rate higher mg dose dupi
abrocitinib mg dupi past mg
howev factor abrocitinib includ sae
higher mg arm includ case ibd
peritonsil dehydr asthma
contend power dupi franchis
year head start launch
sister jade detail data still yet
present data jade compar trial
dupi compar expect
topic ruxolitinib incy/nv data promis
patient less sever diseas japan tobacco also
late stage topic jak inhibitor ad recent
file approv japan
competitor trial read out
asthma comp includ antagonist nvss fevipipr gosss amgn/azn
tezepelumab ad front jak inhibitor continu encroach dupi ad franchis
addit competitor dupix indic
nasal polyp xolair roche/nv trial met endpoint np score chang averag daili nasal
congest score also approv asthma see crswnp market margin driver
also nasal polyp lyra medic stent would compet xent steroid releas
high hope etokimab anab inhibitor mute regn inhibitor
unabl show greater efficaci benefit dupi mono asthma
etokimab posit biolog earli benefit compar dupi/fasenra azn
trial trial eosinophil asthma cell/l expect initi
data etokimab on-going atla trial mod-to-sever ad also expect well
eclips trial top-lin data adult crswnp
derm recent releas data show encourag result dose arm might fallen
short efficaci compar basi derm initi two studi lebrikizumab
studi evalu mg lebri sc week re-random pt pbo
top-line data wont report
anoth ad comp watch report posit result atop dermat antibodi bermekimab toward
last year upcom second trial treat mod-to-sever adult
eq initi uncontrol mod-to-sever asthma
june target antibodi itolizumab
report posit data inhal jak td-
drug well toler mild asthmat
reduc feno level part extens trial
assess addit biomark sever asthma
iga wk
wk
wk
dupix competitor activ across ad asthma crswnp howev time competitor launch
face entrench product efficaci benefit across multipl indic
praluent injunct reduct approv
tit-for-tat price cut brought repatha praluent
regn/sni list price
price caus w/w praluent sale declin
sale recov w/w
declin w/w sale
label includ cvd risk-reduct benefit high risk
cv pt
report pristin safeti data pbo adjust declin
ldl rel baselin trial note
praluent/repatha
conveni dose hefh
ascvd report posit top-lin result detail data
aha mdco expect file fda
european file earli
inclisiran may threaten antibodi differ price
 busi back usual
delawar district court rule amgn patent claim
invalid base lack enabl regn/sni
invalid amgn patent claim hope
curtain saga drawn close least
due sluggish launch praluent franchis still cost
center explor way address sni
praluent franchis breath sigh relief court rule favor regn/sni regard
amgn patent contest howev franchis remain unprofit activ seek
way address project sale ww
develop oncolog waterfront
libtayo sale consist beat estim albeit small total sale number serv
anchor point regn oncolog ambit compani follow multi-
prong strategi encompass
collabor extend car-t therapi novel target
moieti tcr reagent bind peptide/mhc complex
weve affirm mani know launch podcast oncolog launch may
offer lucr return although sunk cost also high
propel ahead bispecif
potenti pivot trial bispecif on-going multi-arm studi
enrol sever cohort r/r non-hodgkin lymphoma pt includ fl dlbcl
result replic demonstr trial believ may
potenti registr
antibodi trial small fatal advanc lymphoma
patient enhanc cytokin releas syndrom may associ increas tumor respons
like caus howev believ unfortun set back overcome- adjust dose regimen
trial continu partial clinic hold
potenti turn cell car-t like cancer killer
clinic
trial mm
data encourag
present
look forward regn costimulatori
bispecif portfolio use
signal activ t-cell
first costimulatori candid
on-going
sever bispecif variou stage develop includ potenti registr trial
fl dlbcl nhl offer import catalyst come year
bcma bispecif expect present earli readout
libtayo sale vs approv eu juli major
step develop cscc adjuv initi neoadjuv set
expect initi pivot studi data also expect
howev signific commerci opportun libtayo lie nsclc libtayo
opportun antibodi approv monotherapi treatment
pivot trial on-going
recist trial enrol
plan patient expect
fulli enrol year end interim os
data expect
first pt show orr
libtayo patient chemo
primari outcom use recist
os enrol approxim
patient expect complet enrol
libtayo abl anchor small cscc market although mrk pembro catch
data present esmo much larger ambit nsclc
indic updat nsclc program expect
class safeti risk continu plagu anti-ngf
regn/teva fasinumab complet enrol long term safeti wk
efficaci studi knee/hip oa pain data expect
howev base pfe/lli tanezumab limit efficaci face elev safeti concern
rpoa total joint replac ascrib valu fasinumab posit readout would
upsid expect
major rpoa
regn/teva pfe/lli press releas
case case sif
rpoa type
like pfe/lli data also expect fasinumab trial durat increas incid safeti
events/joint replac similarli increas
pfe/lli still seem confid enough file drug commentari suggest
opportun believ
regn/teva ngf inhibitor fasinumab still trial knee/hip oa pain given
tanezumab poor show far elev safeti risk limit pain/funct benefit rel
nsaid high safety/efficaci bar surpass regulatori approv commerci viabil
kevzara antibodi look lead market opportun sc class
regn/sni acknowledg disappoint total perform
trial polymyalgia rheumatica giant cell arter well trial polyarticular cours
system juvenil idiopath arthriti
pozelimab antibodi initi studi paroxysm nocturn hemoglobinuria pnh take
alxn soliris/ultomiri dose schedul attempt mitig serum sick caus
antibody/complement/antibodi complex data present
furthermor regn partnership give access rnai complement knockdown
bridg switch serum sick
evinacumab antibodi posit result hofh report file expect
earli next year therapi show pbo adj reduct ldl-cholesterol even take lipid
lower therapi includ statin inhibitor ezetimib apheresi lomatipid baselin
still hypercholesterolemia sever hypertriglyceridemia
also monitor akca competitor program famili
chylomicronemia syndrom data expect
garetosmab antibodi activin potenti pivot studi fibrodysplasia ossifican progressiva
read termin muscl wast studi trevogrumab antibodi myostatin
antibodi allerg asthmat come result report mo
sever catalyst expect next month time frame includ first look
pozelimab trial pnh
 eylea net sale repres
overal brand market
high potenti dr expect satisfi
launch
 eylea net sale repres
overal brand market
high potenti dr patient
moder severe/sever
diseas expect launch pre-fil
syring pend approv
inventori decreas within normal
market share expect
lipid lower treament guidelin
updat facilit greater
made great stride remov access
aford barrier sale
benefit coverag
higher rebat expect
overal brand market
overal brand market
sale attribut namd
come diabet
diabet largest growth
opportun expect launch pre-
fill syring pend
fda approv april prevent
reduc cv risk adult
ascvd avail list price
sale price effect
volum effect injunct german
court due advers court rule
argumenet take palc aug
 district court district
invalid base lack enabl
regn/sni success
invalid assert
nrbx
prescrib written least
sequentila increas trx
increas sequenti
live cover
qoq nearli yoy increas
number provid
prescrib dupi pt
grew compr
prescrib written rx
pt asthma patient new
biolog crswnp
pt highest need
fail one surgeri
ou sale
insur live
medicar
physician
written
nrx share within sc
nbrx share share
reimburs coverag
nbrx share
nbrx
leverag expertis car-t
new target
understand
continu collabor
collabor allow
platform focus ocular/cn
select liver target
profit first time
enact tax cut job
plan
enact tax cut
associ plan
npdr pdufa date may
brand market sale increas driven
pre-fil syring expect launch
brand market plan initi
clincial develop higher dose
pre-fil syring expect launch
fda approv pre-fil syring launch
expect studi wet initi
studi retinopathi prematur initi
cv risk reduct pdufa april
ema approv label extens cv risk
reduct march fda approv reduc
risk cv event april
injunct hear on-going oral
injunct rule favor regn/sni found
initi giant cell arter
initi giant cell arter
dupix asthma patient new
biolog regulatori decis eu/japan
launch countri end
detail result nasal polyp trial
present futur medic meet
dupix asthma patient new
dupix asthma patient new
dupix asthma patient new biolog
fda grant prioriti review crswnp
june approv fda crswnp
octob approv ec crswnp
continu launch ad rest world
chmp recommend approv eu
sever asthma adult/adolesc
japan
may approv ec adults/adolesc
new studi intiiat prurigo nodulari
bullou pemphigoid urticari
adolesc ad ema approv launch
approv ad adolesc
ec approv adolexc ad august
announc data peidatr ad
august extend approv ec adolesc
w/ moder sever ad sever ad met
primari secondari endpoint submiss
bla
trial food grass allergi on-going
collabor aimmun peanut
dupix copd process
initi
trial on-going may identifi
minim effect dose mitig
arthropathi safeti signal stop
signal far
recommend program continu
trail on-going data
trail on-going data
 launch on-going ema approv launch
approv canada cscc april brazil
like studi adjuv set
commenc neo-adjuv set
march initait trial cscc adjuv neo-
june approv ec cscc adjuv studi initait
adjuv studi on-going neoadjuv studi initi
studi follow
approv adult cscc
studi local advanec conort enrol
trial expect
hypercholesterolemia sever
hypercholesterolemia sever
readout end year
studi mono/combo
asthma ad copd report asthma studi
studi ad initi mono
combo dupi
first poc trial read-out asthma mid
poc asthma data report combo
demonstr increas benefit dupi mono interim
result copd ad expect next month
interim result copd ad expect next
compel data fl dlbcl initi
pivot trial fl dlbcl
fatal potenti relat
activ enrol patient pivot fl dlbcl
nhl subtyp studi
activ enrol patient pivot fl dlbcl
initi pnh
present antibodi data pnh end year
present antibodi data pnh end year
studi initi met-advanc nsclc
phase data fop end year
phase data fop end year
trial investig therapi stop earli
extens phase trial on-going breakthrough design
fda roll bla submiss initi
enter clinic mm
first co-stimulatori co-steam bispecif soon
present preliminari data end multipl
present preliminari data end multipl
studi initi prostat cancer
collabor serv exclus
partner ocular/cn indic
collabor select liver target
introduc costimulatori bispecif
pen
pre-filled exchang
dose
syring
inform inc wkcdi endors data view opinion find express herein
document materi prepar behalf evercor isi employe
chart highlight arrow
price earn
price-to-earnings growth ratio ntm
npv
npv fcf-per-share
arget market cap impli pt
target ev impli pt
growth rate
share sni jv
teva reimburs
share base comp sg
incom oper
adjust oper incom
inc account receiv
increas inventori
increas account payabl liabil
oper
invest
proce leas oblig
payment leas oblig
payment warrant reduct
financ
chang cash/equiv
deriv pt use dcf discount rate termin growth rate reflect compani engin discount
rate standard rate appli across derisk biopharma compani reflect believ appropri return sharehold pt
repres price-to-earnings multipl non-gaap ep estim meaning premium averag price-to-earnings multipl compani peer group
justifi view nt growth outlook driven dupix engin seem pois deliv blockbust therapi
risk includ pipelin failur commerci execut failur generic/biosimilar entri dupix may face competit threat fail meet consensu
expect becom blockbust therapi praluent may pull market result on-going patent litig eylea may
face new competit reimburs headwind
articl articl
time dissemin novemb
analyst josh schimmer neeraj koduri angela ni maneka mirchandaney primarili respons prepar research report attest follow view
opinion render research report reflect person view subject compani issuer part research analyst compens
directli relat specif recommend view research report
